September

Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Vincent Cottin Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Rare pulmonary disease and orphan drugs: a path to the future Sergio Harari, Yochai Adir, Marc Humbert Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019
Particulate matter and the airway epithelium: the special case of the underground? Dawn M. Cooper, Matthew Loxham Eur Respir Rev, 28 (153) 190066; 10.1183/16000617.0066-2019
Cellular mechanisms underlying steroid-resistant asthma Ridhima Wadhwa, Kamal Dua, Ian M. Adcock, Jay C. Horvat, Richard Y. Kim, Philip M. Hansbro Eur Respir Rev, 28 (153) 190096; 10.1183/16000617.0096-2019
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Bridget F. Collins, Ganesh Raghu Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
The therapy of idiopathic pulmonary fibrosis: what is next? Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
What have we learned from basic science studies on idiopathic pulmonary fibrosis? Toyoshi Yanagihara, Seidai Sato, Chandak Upagupta, Martin Kolb Eur Respir Rev, 28 (153) 190029; 10.1183/16000617.0029-2019
The genetics of interstitial lung diseases Raphael Borie, Pierre Le Guen, Mada Ghanem, Camille Taillé, Clairelyne Dupin, Philippe Dieudé, Caroline Kannengiesser, Bruno Crestani Eur Respir Rev, 28 (153) 190053; 10.1183/16000617.0053-2019
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Jacques Cadranel, Anthony Canellas, Lise Matton, Marie Darrason, Antoine Parrot, Jean-Marc Naccache, Armelle Lavolé, Anne-Marie Ruppert, Vincent Fallet Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019
Pulmonary hypertension and chronic lung disease: where are we headed? Davide Elia, Antonella Caminati, Maurizio Zompatori, Roberto Cassandro, Chiara Lonati, Francesca Luisi, Giuseppe Pelosi, Steeve Provencher, Sergio Harari Eur Respir Rev, 28 (153) 190065; 10.1183/16000617.0065-2019
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue Antonella Caminati, Chiara Lonati, Roberto Cassandro, Davide Elia, Giuseppe Pelosi, Olga Torre, Maurizio Zompatori, Elisabetta Uslenghi, Sergio Harari Eur Respir Rev, 28 (153) 190044; 10.1183/16000617.0044-2019
Treating restless legs syndrome in the context of sleep disordered breathing comorbidity Sofía Romero-Peralta, Irene Cano-Pumarega, Celia Garcia-Malo, Lina Agudelo Ramos, Diego García-Borreguero Eur Respir Rev, 28 (153) 190061; 10.1183/16000617.0061-2019
New organisation for follow-up and assessment of treatment efficacy in sleep apnoea Monique Suarez-Giron, Maria R. Bonsignore, Josep M. Montserrat Eur Respir Rev, 28 (153) 190059; 10.1183/16000617.0059-2019
Sleep in chronic respiratory disease: COPD and hypoventilation disorders Walter T. McNicholas, Daniel Hansson, Sofia Schiza, Ludger Grote Eur Respir Rev, 28 (153) 190064; 10.1183/16000617.0064-2019
Update on oral appliance therapy Marie Marklund, Marc J.A. Braem, Johan Verbraecken Eur Respir Rev, 28 (153) 190083; 10.1183/16000617.0083-2019
Management of insomnia in sleep disordered breathing Hennie C.J.P. Janssen, Lisette N. Venekamp, Geert A.M. Peeters, Angelique Pijpers, Dirk A.A. Pevernagie Eur Respir Rev, 28 (153) 190080; 10.1183/16000617.0080-2019
“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021. Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019